Fenwick Represents BioAge Labs in $238 Million Upsized Initial Public Offering and Concurrent Private Placement

Fenwick represented BioAge Labs, Inc. (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, in its upsized initial public offering of 12,650,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 1,650,000 additional shares, at a public offering price of $18.00 per share. BioAge also completed the sale of 588,888 shares of its common stock at the public offering price per share in a concurrent private placement to an existing shareholder. The shares began trading on the Nasdaq Global Market on September 26, 2024. The gross proceeds from the offering and private placement were approximately $238 million.

Goldman Sachs & Co. LLC, Morgan Stanley, Jefferies, and Citigroup are acting as joint book-running managers for the offering. More information can be obtained from BioAge’s announcement.

The Fenwick team included corporate partners Matt Rossiter, Rob Freedman, Julia Forbess and Michael Pilo and associates Adam Conway, Meg Moloney, Lindsey Macalalad and Phillip Craig; technology transactions partner Jake Handy; executive compensation and employee benefits partner Liz Gartland and associate Christophe Delriue; privacy and cybersecurity counsels Sari Ratican and Melanie Jolson; and patent partner Dan Becker and associate Glenn Foulds.